Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Erytech Pharma’s technology makes it possible to “starve” cancer cells by depriving them of their nutrients. The principle of this innovative treatment is to eliminate circulating asparagine using a specific enzyme: L-asparaginase. This enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
Erytech makes it possible to turn a red blood cell into a cellular bioreactor. GRASPA consists of red blood cell-encapsulated L-asparaginase that, thanks to the encapsulation, enables the enzyme to destroy asparagine inside the red blood cell, preventing allergic reactions and reducing other adverse events.
The drug candidate was tested in patients with Acute Lymphoblastic Leukemia (ALL), in which side effects were significantly reduced, demonstrating a lower risk of hypersensitivity reactions. The favorable efficacy and safety profile of GRASPA offers an effective alternative option for patients who have received prior asparaginase therapy, including patients who had experienced prior hypersensitivities to E. Coli derived asparaginases.